美国临床肿瘤学会多基因检测临床实践指南更新及临床意义
Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer

DOI: 10.6040/j.issn.1671-7554.0.2017.1074

Keywords: 乳腺癌,多基因检测,MammaPrint^？,,美国临床肿瘤学会,
American Society of Clinical Oncology,Breast cancer,Multigene tests,MammaPrint^？,

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[2]	Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2016.
[3]	Campbell HE, Taylor MA, Harris AL, et al. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom[J]. Br J Cancer, 2009, 101(7): 1074-1084.
[4]	Olivotto IA, Bajdik CD, Ravdin PM, et al. Population based validation of the prognostic model ADJUVANT! for early breast cancer[J]. J Clin Oncol, 2005, 23(12): 2716-2725.
[5]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[6]	Liedtk C, Thil M, Jackisch C, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017[J]. Breast Care, 2017, 12(3): 172-183.
[7]	van de Vijver MJ, He YD, vant Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347: 1999-2009.
[8]	Adjuvant! Online Web Site. http://www.adjuvantonline.com.
[9]	Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer[J]. J Clin Oncol, 2001, 19(4): 980-991.
[10]	Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study[J]. Lancet Oncol, 2009, 10(11): 1070-1076.
[11]	Hajage D, de Rycke Y, Bollet M, et al. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement[J]. PLoS One, 2011, 6(11): e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.
[12]	Prosigna<sup>？</sup>, PAM 50 Web Site. https://www.nanostring.com/diagnostics/prosigna.
[13]	Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2017, 35(24): 2838-2847.
[14]	Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl~5): 8-30.
[15]	Buyse M, Loi S, vant Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[16]	Cardoso F, Vant Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial[J]. J Clin Oncol, 2008, 26(5): 729-735.
[17]	Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers(EGTM)[J]. Eur J Cancer, 2017, 75: 284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
[18]	Oncotype DX<sup>？</sup> Web Site. http://www.oncotypedx.com.
[19]	EndoPredict<sup>？</sup> Web Site.http://www.endopredict.com/en/home.html.
[20]	vant Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[21]	Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Annals of Oncol, 2011, 22(8): 1736-1747.
[22]	Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial[J]. Nat Clin Pract Oncol, 2006, 3(10): 540-551.
[23]	Users Guide for Adjuvant! Version 8.0, Dec 2005.
[24]	Breast Cancer Index Web Site. https://www.breastcancerindex.com.
[25]	江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.

Full-Text